Based on current market conditions and assuming that macroeconomic trends, including tariff policy, inflation, interest rate levels and supply chain costs do not materially impede activity in the medical technology industry generally, or for the Company specifically, the Company anticipates that the number of clinical, demo, and commercial units in various stages of deployment will grow to over 100 units by the end of 2025, on a worldwide basis.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NNOX:
- Options Volatility and Implied Earnings Moves Today, November 20, 2025
- Vaso Corporation to sell VasoHealthcare IT to Nano-X Imaging
- Nanox Imaging to Acquire VasoHealthcare IT for U.S. AI Expansion
- Nano-X Imaging to acquire VasoHealthcare IT from Vaso
- Nano-X announces strategic partnership with 3DR Labs